Chemoprevention of Oral Premalignant Lesions

Completed · Phase 2

Conditions studied: Precancerous Conditions

In brief

Reduction in size and number of oral premalignant lesions

Key facts

Study ID

NCT00036283

Run by

Pfizer

People needed

42

Starts

2000-11-01

Expected to finish

2004-04-01

Last updated by the study team

2008-09-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 8mm oral premalignant lesion that has not been biopsied in the past 6 months

You may not qualify if…

• Taking >100mg daily dose of NSAIDS (Non-steroidal anti-inflammatory drugs)

Where it is running

• Pfizer Investigational Site — Farmington, Connecticut, United States
• Pfizer Investigational Site — Shreveport, Louisiana, United States
• Pfizer Investigational Site — Ann Arbor, Michigan, United States
• Pfizer Investigational Site — Minneapolis, Minnesota, United States
• Pfizer Investigational Site — New York, New York, United States
• Pfizer Investigational Site — Houston, Texas, United States
• Pfizer Investigational Site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.